Literature DB >> 35342470

Coronavirus as a Trigger Of Graves' Disease.

A M Urbanovych1, F Laniush1, M Borovets1, K Kozlovska1.   

Abstract

Context: SARS-CoV-2 infection was declared a pandemic in 2020 and affected millions of people worldwide. Angiotensin-converting enzyme-2 receptors, through which coronavirus enters the cells of different organs, have been detected in the thyroid gland. The most common cause of thyrotoxicosis is Graves' disease in which thyroid-receptors antibodies (TRAb) stimulate the TSH receptor, increasing thyroid hormone production and release. Case presentation: A 22-year-old woman had symptoms of palpitation, tremor, muscle weakness, anxiety and sleep disturbance. 3 weeks before the onset of these symptoms, the patient suffered from COVID-19, which lasted 14 days and was characterized by a course of moderate severity with fever up to 38°C, general weakness without shortness of breath. The patient had no pre-existing thyroid problems. Her TSH was <0.01 mU/L, FT4, FT3 and TRAb were increased. Antithyroid drugs, glucocorticosteroids and β-blockers were prescribed. During 3 months of treatment doses of methimazole, methylprednisolone and bisoprolol were gradually reduced due to the improvement of the patient's condition and thyroid tests normalization. Conclusions: COVID-19 infection can cause Graves' disease and thyrotoxicosis. The onset of this disease after SARS-CoV-2 does not depend on the presence of pre-existing thyroid pathology and requires the appointment of glucocortisteroids. ©2021 Acta Endocrinologica (Buc).

Entities:  

Keywords:  ACE2; Graves’ disease; SARS-CoV-2; thyrotoxicosis

Year:  2021        PMID: 35342470      PMCID: PMC8919476          DOI: 10.4183/aeb.2021.413

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  12 in total

Review 1.  Nongenomic actions of thyroid hormone.

Authors:  Paul J Davis; Fernando Goglia; Jack L Leonard
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

Review 2.  Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship?

Authors:  Paul J Davis; Hung-Yun Lin; Aleck Hercbergs; Kelly A Keating; Shaker A Mousa
Journal:  Endocr Res       Date:  2020-08       Impact factor: 1.720

Review 3.  Graves' Disease.

Authors:  Terry J Smith; Laszlo Hegedüs
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

Review 4.  Impact of COVID-19 on the thyroid gland: an update.

Authors:  Lorenzo Scappaticcio; Fabián Pitoia; Katherine Esposito; Arnoldo Piccardo; Pierpaolo Trimboli
Journal:  Rev Endocr Metab Disord       Date:  2020-11-25       Impact factor: 6.514

Review 5.  Hyperthyroidism.

Authors:  Simone De Leo; Sun Y Lee; Lewis E Braverman
Journal:  Lancet       Date:  2016-03-30       Impact factor: 79.321

6.  SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19.

Authors:  M Mateu-Salat; E Urgell; A Chico
Journal:  J Endocrinol Invest       Date:  2020-07-19       Impact factor: 4.256

7.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors:  Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal:  Science       Date:  2020-03-04       Impact factor: 47.728

Review 8.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.

Authors:  Yan-Rong Guo; Qing-Dong Cao; Zhong-Si Hong; Yuan-Yang Tan; Shou-Deng Chen; Hong-Jun Jin; Kai-Sen Tan; De-Yun Wang; Yan Yan
Journal:  Mil Med Res       Date:  2020-03-13

9.  Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic.

Authors:  Rosaria Maddalena Ruggeri; Alfredo Campennì; Massimiliano Siracusa; Giuseppe Frazzetto; Damiano Gullo
Journal:  Hormones (Athens)       Date:  2020-07-16       Impact factor: 2.885

10.  Thyrotoxicosis in patients with COVID-19: the THYRCOV study.

Authors:  Andrea Lania; Maria Teresa Sandri; Miriam Cellini; Marco Mirani; Elisabetta Lavezzi; Gherardo Mazziotti
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.